Nausea and vomiting associated with chemotherapy and principles of management in their prevention

Katarzyna Łysiak; Anna Łysiak; Barbara Maziarz; Paulina Przywara; Natalia Bogumiłło; Kinga Ściurka; Julia Ignacak; Mikołaj Borek; Oliwia Grzelak

doi:10.56782/pps.227

Published : 2025-02-25

Vol. 23 No. 1 (2025)

Nausea and vomiting associated with chemotherapy and principles of management in their prevention

Katarzyna Łysiak

Anna Łysiak

Barbara Maziarz

Paulina Przywara

Natalia Bogumiłło

Kinga Ściurka

Julia Ignacak

Mikołaj Borek

Oliwia Grzelak

DOI: https://doi.org/10.56782/pps.227

Abstract

Nowadays, there are many effective cancer treatments that use different combinations of chemotherapeutics agents to destroy cancer cells, often in advanced stages when radical surgery methods are no longer possible. Unfortunately, the toxicity of treatment can cause many side effects. One of them is nausea and vomiting, which significantly affects the quality of life and is a challenge for cancer patients. Nausea and vomiting affect 40-80% of patients receiving chemotherapy and/or radiotherapy. The likelihood of their occurrence depends on the treatment regimen, dose and route of administration. Of course, patient-related factors also play a role. The use of combination antiemetics, including setrons in combination with a neurokinin-1 (NK-1) receptor antagonist and glucocorticosteroids, can effectively prevent nausea and vomiting - in the early type in about 80-90% of patients and in the late type in about 60-80%. Nausea and vomiting can significantly reduce the quality of life of patents undergoing cancer treatment. However, adherence to an appropriate treatment regimen ensures that patients have an optimal quality of life during treatment. This article discusses current strategies for the prevention and treatment of nausea and vomiting using antiemetic drugs.

Keywords:

vomiting, nausea, chemotherapy, guidelines, glucocorticosteroids

Similar Articles

Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Szymon Barczak, Barbara Badura, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało, Severe course of HIV-related Kaposi’s sarcoma with cutaneous, visceral and oral manifestations in a late-presenting patient , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Agata Pisula, Agnieszka Sienicka, Agnieszka Dobrowolska-Redo, Joanna Kacperczyk-Bartnik, Ewa Romejko-Wolniewicz, PARP inhibitors in ovarian cancer therapy , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and safety of bempedoic acid in lipid disorder therapy: a review of clinical trials , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and other chemical substances inducing diabetes – review of the literature , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Anna Lis, Paulina Lis, Wojciech Kaźmierski, Kinga Kocur, Katarzyna Camlet, Jakub Jurek, Mateusz Ziomek, Anna Ziobro, Sodium bicarbonate - known medication, new prospects? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Michał Dacka, Mateusz Sobczyk , Paulina Dąbrowska , Kamila Giżewska , Michał Żuber , Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Bartłomiej Kałaska, Joanna Mikłosz, Emilia Sokołowska, Andrzej Mogielnicki, THE PROS AND CONS OF MODERN ANTICOAGULANT THERAPY , Prospects in Pharmaceutical Sciences: Vol. 14 No. 10 (2016)
Adam Piasecki, Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
Aleksandra Białczyk, Gabriela Leśniak, Filip Nadolny, Justyna Mrowiec, Antoni Otałęga, Exploring digital health horizons: a narrative review of e-health innovations in Poland, Spain, Romania and Estonia. , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)

1 2 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Łysiak, K., Łysiak, A., Maziarz, B., Przywara, P., Bogumiłło, N., Ściurka, K., … Grzelak, O. (2025). Nausea and vomiting associated with chemotherapy and principles of management in their prevention. Prospects in Pharmaceutical Sciences, 23(1), 74–79. https://doi.org/10.56782/pps.227

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Wojtyniak, B.; Goryński, P. Health Status of Polish Population and Its Determinants 2022. National Institute of Public Health NIH – National Research Institute: Warsaw, Poland, 2022, pp. 271-292.

2. Wojciechowska, U.; Barańska, K.; Michałek, I.; Olasek, P.; Miklewska, M.; Didkowska, J. Nowotwory złośliwe w Polsce w 2020 roku [Cancer in Poland in 2020]. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii [National Cancer Registry, National Cancer Institute]: Warsaw, Poland, 2022; p. 3.

3. National Cancer Registry. Available online: https://onkologia.org.pl/pl/nowotwory/leczenie (accessed on 01.08.2023)

4. Strąg-Lemanowicz, A.; Leppert, W. The role of oncologic systemic treatment in patients with advanced cancer. Palliat. Med. Pract. 2014, 8, 11 – 22.

5. Rubach, M. Objawy niepożądane chemioterapii (cz. 1) [Adverse effects of chemotherapy]. Onkologia po Dyplomie [Oncology after the diploma] 2019, 04. Available online: https://podyplomie.pl/onkologia/33141,objawy-niepozadane-chemioterapii-cz-1?srsltid=AfmBOopjhspw1GFq4R639Mau_5MsDEOQA9-a3cN0Tws9KMWSwxGMc-m9 (accessed 02.08.2023)

6. Kawecki, A.; Krzakowski, M. Chemotherapy and radiotherapy induced nausea and vomiting. Oncol. Clin. Pract. 2018, 14, 53–61. DOI: 10.5603/OCP.2018.0010, copyright

7. Sullivan, J.R.; Leyden, M,J.; Bell, R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N. Engl. J. Med. 1983, 309, 796-796. DOI: 10.1056/NEJM198309293091317 DOI: https://doi.org/10.1056/NEJM198309293091316

8. Tonato, M.; Roila, F.; Del Favero, A. Methodology of antiemetic trials: a review. Ann. Oncol. 1991, 2, 107-114. DOI: 10.1093/oxfordjournals.annonc.a057871 DOI: https://doi.org/10.1093/oxfordjournals.annonc.a057871

9. Hesketh, P.J.; Kris, M.G.; Basch, E.; et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2017, 35, 3240-3261. DOI: 10.1200/JCO.2017.74.4789 DOI: https://doi.org/10.1200/JCO.2017.74.4789

10. Szczeklik, A; Gajewski P. Nausea and vomiting. In Szczeklik's Interna: small textbook 2022/2023, 14nd ed.; Krzakowski, M.; Sacha, T.; Krzemieniecki, K.; Practical Medicine: Cracow, Poland, 2022.

11. Mannix, K.A.; Hardy, J.R.; Glare, P.; Yates, P. Palliation of nausea and vomiting. In Oxford Textbook of Palliative Medicine, 5th ed.; Cherny, N.I.; Fallon, M.T.; Kaasa, S.; Portenoy, R.K.; Currow, D.C., Eds.; Oxford University Press: Oxford, UK, 2015, pp. 661-675. DOI: https://doi.org/10.1093/med/9780199656097.003.0202

12. Ripamonti, C.; Bruera, E. Chronic nausea and vomiting. In Gastrointestinal Symptoms in Advanced Cancer Patients, 1st ed.; Ripamonti, C.; Bruera, E., Eds.; Oxford University Press: Oxford, UK, 2002, pp. 169-192. DOI: https://doi.org/10.1093/oso/9780192632845.003.0008

13. Roila, F.; Molassiotis, A.; Herrstedt, J.; et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 2016, 27, 119–133, DOI: 10.1093/annonc/mdw270 DOI: https://doi.org/10.1093/annonc/mdw270

14. Sutherland, A.; Naessens, K.; Plugge, E.; Ware, L.; Head, K.; Burton, M.J.; Wee, B. Olanzapine in the prevention and treatment of vomiting and nausea associated with cancer in adults. Cochrane Database Syst. Rev. 2018, 9, Art. No: CD012555. DOI: 10.1002/14651858.CD012555.pub2 DOI: https://doi.org/10.1002/14651858.CD012555.pub2

15. Leppert, W.; Łuczak, J. Treatment of nausea and vomiting in advanced cancer, Contemp. Oncol. 2003, 7, 504–527

16. Piechal, A.; Blecharz-Kliin, K. Leki przeciwwymiotne [Antiemetics]. Medycyna po dyplomie [Medicine after the diploma] 2014, 03. Available online: https://podyplomie.pl/medycyna/16197,leki-przeciwwymiotne?srsltid=AfmBOopYQdutkcUZHAegLUKekNZVHEIZWTRiYHXNEmd7Fz1Vl9KlODwU (accessed 03.08.2023)

17. Gilmore, J.; D’Amato, S.; et al. Recent yadvances in antiemetics: new formulations of 5HT3-receptor antagonists. Cancer Manag. Res. 2018, 10, 1827-1857. DOI: 10.2147/CMAR.S166912 DOI: https://doi.org/10.2147/CMAR.S166912

18. Dadej, A.; Dadej, D.; Michałowska, M.; Tomczak, Sz.; Zając, M.; Jelińska, A. Antagonists of 5-HT3 serotonin and NK-1 neurokinin receptors in the management of chemotherapy-related early and late vomiting. Mod. Pharm. 2019, 12, 134-141.

19. Scannell, C.; Ryan, A.; Power, D.; Hanna, M.; O’Sullivan, A.; Mulcahy, K.; Dolan, O. The Truth Behind Food & Cancer: Simple Explanations Based on Scientific Evidence; 1st ed.; Cork University Press: Cork, Ireland, 2022, pp. 34-36. DOI: https://doi.org/10.33178/boolean.2022.1.24

20. Leppert, W.; Wache A. Nudności i wymioty wywołane chemioterapią i radioterapią u chorych na nowotwory [Nausea and vomiting induced by chemotherapy and radiotherapy in cancer patients]. Onkologia po dyplomie [Oncology after the diploma]. 2014, 05. Available online: https://podyplomie.pl/onkologia/17162,nudnosci-i-wymioty-wywolane-chemioterapia-i-radioterapia-u-chorych-na-nowotwory?srsltid=AfmBOookfMVtBW7dauIcZ8Z9_R5w_RxOBX_hXjOHH_mi9HoyqqqiuHFl (accessed 02.08.2023).

21. Rao, K.V.; Faso, A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am. Health Drug Benefits. 2012, 5, 232-240.

22. Dennis, K.; Maranzano, E.; De Angelis, C.; et al. Radiotherapy-induced nausea and vomiting. Expert Rev. Pharmacoecon. Outcomes Res. 2011, 11, 685-692. Doi: 10.1586/erp.11.77 DOI: https://doi.org/10.1586/erp.11.77

23. Maranzano, E.; De Angelis, V.; Pergolizzi, S.; et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother. Oncol. 2010, 94, 36-41. DOi: 10.1016/j.radonc.2009.11.001 DOI: https://doi.org/10.1016/j.radonc.2009.11.001

24. Horiot, J.C. Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting? Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 1018-1025. DOI: 10.1016/j.ijrobp.2004.07.722 DOI: https://doi.org/10.1016/j.ijrobp.2004.07.722

25. Aass, N.; Håtun, D.E.; Thoresen, M.; et al. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother. Oncol. 1997, 45, 125-128. DOI: 10.1016/s0167-8140(97)00099-6 DOI: https://doi.org/10.1016/S0167-8140(97)00099-6

26. Bey, P.; Wilkinson, P.M.; Resbeut, M.; et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support. Care Cancer 1996, 4, 378-383. DOI: 10.1007/BF01788845 DOI: https://doi.org/10.1007/BF01788845

27. Franzén, L.; Nyman, J.; Hagberg, H.; et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann. Oncol. 1996, 7, 587-592. DOI: 10.1093/oxfordjournals.annonc.a010675 DOI: https://doi.org/10.1093/oxfordjournals.annonc.a010675

28. Lanciano, R.; Sherman, D.M.; Michalski, J.; et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest. 2001, 19, 763-772. DOI: 10.1081/cnv-100107736 DOI: https://doi.org/10.1081/CNV-100107736

29. Priestman, T.J.; Roberts, J.T.; Upadhyaya, B.K. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin. Oncol. (R. Coll. Radiol.). 1993, 5, 358-363. DOI: 10.1016/s0936-6555(05)80086-x DOI: https://doi.org/10.1016/S0936-6555(05)80086-X

30. Chow, E.; Zeng, L.; Salvo, N.; et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin. Oncol. (R. Coll. Radiol.). 2012, 24, 112-124. DOI: 10.1016/j.clon.2011.11.004 DOI: https://doi.org/10.1016/j.clon.2011.11.004

31. Dennis, K.; Nguyen, J.; Presutti, R.; et al. Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases. Support. Care Cancer 2012, 20, 1673-1678. DOI: 10.1007/s00520-011-1258-x DOI: https://doi.org/10.1007/s00520-011-1258-x

32. Kirkbride, P.; Bezjak, A.; Pater, J.; et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J. Clin. Oncol. 2000, 18, 1960-1966. DOI: 10.1200/JCO.2000.18.9.1960 DOI: https://doi.org/10.1200/JCO.2000.18.9.1960

33. Roila, F.; Herrstedt, J.; Gralla, R.J.; Tonato, M. Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference. Support. Care Cancer 2011, 19, 63-65. DOI: 10.1007/s00520-010-1044-1 DOI: https://doi.org/10.1007/s00520-010-1044-1

34. Molassiotis, A.; Stamataki, Z.; Kontopantelis, E. Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support. Care Cancer 2013, 21, 2759-2767. DOI: 10.1007/s00520-013-1843-2 DOI: https://doi.org/10.1007/s00520-013-1843-2

35. Pasternak, B.; Svanström, H.; Hviid, A. Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes. N. Engl. J. Med. 2013, 368, 814-823. DOI: 10.1056/NEJMoa1211035 DOI: https://doi.org/10.1056/NEJMoa1211035

Nausea and vomiting associated with chemotherapy and principles of management in their prevention

Katarzyna Łysiak

Anna Łysiak

Barbara Maziarz

Paulina Przywara

Natalia Bogumiłło

Kinga Ściurka

Julia Ignacak

Mikołaj Borek

Oliwia Grzelak

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Katarzyna Łysiak

Anna Łysiak

Barbara Maziarz

Paulina Przywara

Natalia Bogumiłło

Kinga Ściurka

Julia Ignacak

Mikołaj Borek

Oliwia Grzelak